DSNKY Stock, Daiichi Sankyo Co., Ltd. ADR Information

Daiichi Sankyo was established by the merger of Daiichi Pharmaceuticals and Sankyo in 2005. As of 2021, approximately half of revenue comes from its Japan businesses, which will shrink in the future as the company expands its global footprint. Its primary growth driver is its leading platform of antibody drug conjugates. Its three lead ADCs are Enhertu (HER2), Dato-DXd (TROP2), and HER3-DXd (HER3). Enhertu entered the clinic in 2015 and received its first U.S Food and Drug Administration approval in December 2019 for third-line late-stage HER2-positive breast cancer and its high efficacy is changing the treatment landscape for HER-expressing breast cancers. It is also approved for HER2-positive stomach cancers and HER2 mutant non-small cell lung cancer.